| Literature DB >> 33396374 |
Bryce J B Nelson1, Jan D Andersson1,2, Frank Wuest1.
Abstract
This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α-particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and radiochemistry of common α-emitters, including 225Ac, 213Bi, 224Ra, 212Pb, 227Th, 223Ra, 211At, and 149Tb; the production techniques and proper handling of α-emitters in a radiopharmacy; recent preclinical developments; ongoing and completed clinical trials; and an outlook on the future of TAT.Entities:
Keywords: actinium-225; alpha particle therapy; astatine-211; bismuth-213; radium-223; targeted alpha therapy; targeted radionuclide therapy; terbium-149; theranostics; thorium-227
Year: 2020 PMID: 33396374 PMCID: PMC7824049 DOI: 10.3390/pharmaceutics13010049
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321